Xencor (NASDAQ:XNCR) Hits New 12-Month Low – Here’s What Happened

Xencor, Inc. (NASDAQ:XNCR)’s share price hit a new 52-week low on Tuesday . The stock traded as low as $12.23 and last traded at $12.61, with a volume of 61223 shares. The stock had previously closed at $12.95.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on XNCR shares. Wells Fargo & Company cut their target price on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. Piper Sandler raised Xencor from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $20.00 to $30.00 in a research note on Monday, December 2nd. Finally, StockNews.com cut Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Xencor presently has a consensus rating of “Moderate Buy” and an average target price of $34.38.

Xencor Stock Performance

The firm has a market cap of $868.09 million, a P/E ratio of -3.85 and a beta of 0.74. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The firm has a fifty day moving average of $16.22 and a 200-day moving average of $20.30.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.19. The firm had revenue of $52.79 million for the quarter, compared to analysts’ expectations of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. Research analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Xencor

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC increased its holdings in shares of Xencor by 31.0% in the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 508 shares in the last quarter. KBC Group NV grew its position in shares of Xencor by 26.0% in the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 813 shares during the period. Point72 Asia Singapore Pte. Ltd. increased its stake in Xencor by 8.5% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 12,156 shares of the biopharmaceutical company’s stock worth $244,000 after purchasing an additional 949 shares in the last quarter. Sterling Capital Management LLC raised its holdings in Xencor by 732.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,040 shares during the period. Finally, Summit Investment Advisors Inc. lifted its stake in Xencor by 22.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company’s stock valued at $162,000 after buying an additional 1,282 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.